{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:38:08Z","timestamp":1785537488304,"version":"3.56.0"},"reference-count":32,"publisher":"Akademiai Kiado Zrt.","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Orvosi Hetilap"],"published-print":{"date-parts":[[2015,2]]},"abstract":"The treatment of migraine depends on the frequency, severity and concomitant diseases. There are several specific drugs developed for migraine prevention in addition to the additive antimigraine effects of some other non-specific drugs. The aim of this literature-based review is to summarize the possible antimigraine properties of different antihypertensive agents (beta-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, etc.) focusing on the possible side effects (avoidance of beta blockers in the absence of heart disease, possible antiparkinson effect of calcium channel blockers, additive effect of drugs modifying the renin-angiotensin system activity, etc.). Current evidence supports the use of angiotensin converting enzyme inhibitors (mainly lisinopril) and angiotensin receptor blockers (mainly candesartan) for long-term migraine prevention and blood pressure control. Long-term beta-blocker treatment should be avoided in the absence of ischemic heart disease due to possible unfavourable cardiovascular effects. Orv. Hetil., 2015, 156(5), 179\u2013185.<\/jats:p>","DOI":"10.1556\/oh.2015.30056","type":"journal-article","created":{"date-parts":[[2015,1,25]],"date-time":"2015-01-25T02:01:18Z","timestamp":1422151278000},"page":"179-185","source":"Crossref","is-referenced-by-count":5,"title":["Role of antihypertensive drugs in the treatment of migraine"],"prefix":"10.1556","volume":"156","author":[{"given":"Gergely","family":"Feh\u00e9r","sequence":"first","affiliation":[{"name":"Szigetv\u00e1ri K\u00f3rh\u00e1z Neurol\u00f3giai Oszt\u00e1ly Szigetv\u00e1r"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Pusch","sequence":"additional","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar Neurol\u00f3giai Klinika P\u00e9cs"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"1","unstructured":"www.tankonyvtar.hu\/hu\/tartalom\/tamop425\/0019_2A...\/N_III_2_3.pdf<\/a>"},{"key":"2","unstructured":"College of Neurology: Guideline for the classification, epidemiology, examination and treatment of primary headache syndromes (including criteria of headache centres) [Neurol\u00f3giai Szakmai Koll\u00e9gium:<\/i> Az Eg\u00e9szs\u00e9g\u00fcgyi Miniszt\u00e9rium szakmai protokollja: Az els\u0151dleges fejf\u00e1j\u00e1sok klasszifik\u00e1ci\u00f3j\u00e1r\u00f3l, a migr\u00e9n epidemiol\u00f3gi\u00e1j\u00e1r\u00f3l, a fejf\u00e1j\u00e1sban szenved\u0151 betegek kivizsg\u00e1l\u00e1si strat\u00e9gi\u00e1j\u00e1r\u00f3l \u00e9s az els\u0151dleges fejf\u00e1j\u00e1sok kezel\u00e9s\u00e9r\u0151l (\u00e9s a fejf\u00e1j\u00e1s centrumok krit\u00e9riumair\u00f3l).] Hivatalos \u00c9rtes\u00edt\u0151, 2010, 13<\/i>(30), 6431\u2013 6466. [Hungarian]"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Jackson, J. L., Shimeall, W., Sessums, L., et al.:<\/i> Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ, 2010, 341,<\/i> c5222.","DOI":"10.1136\/bmj.c5222"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS): The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia, 2013, 33<\/i>(9), 629\u2013 808.","DOI":"10.1177\/0333102413485658"},{"key":"5","unstructured":"College of Internal Medicine and Hungarian Society of Hypertension: Guideline of the Ministry of Health: Treatment of hypertension. [A Belgy\u00f3gy\u00e1szati Szakmai Koll\u00e9gium \u00e9s a Magyar Hypertonia T\u00e1rsas\u00e1g:<\/i> Az Eg\u00e9szs\u00e9g\u00fcgyi Miniszt\u00e9rium szakmai ir\u00e1nyelve: A hypertoniabetegs\u00e9g kezel\u00e9se.] Eg\u00e9szs\u00e9g\u00fcgyi K\u00f6zl\u00f6ny, 2008, 58<\/i>(3), 1\u201381. [Hungarian]"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Feher, A., Pusch, G., Koltai, K., et al.:<\/i> Statintherapy in the primary and the secondary prevention of ischaemic cerebrovascular diseases. Int. J. Cardiol., 2011, 148<\/i>(2), 131\u2013138.","DOI":"10.1016\/j.ijcard.2010.08.012"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Casucci, G., Villani, V., Frediani, F.:<\/i> Central mechanism of action of antimigraine prophylactic drugs. Neurol Sci., 2008, 29<\/i>(Suppl 1), S123\u2013S126.","DOI":"10.1007\/s10072-008-0902-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Pringsheim, T., Davenport, W., Mackie, G., et al.:<\/i> Canadian Headache Society guideline for migraine prophylaxis. Can. J. Neurol. Sci., 2012, 39<\/i>(Suppl. 2), S1\u2013S59.","DOI":"10.1017\/S0317167100015109"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Silberstein, S. D., Holland, S., Freitag, F., et al.:<\/i> Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology, 2012, 78<\/i>(17), 1337\u20131345.","DOI":"10.1212\/WNL.0b013e3182535d20"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Evers, S., Afra, J., Frese, A., et al.:<\/i> EFNS guideline on the drug treatment of migraine \u2013 revised report of an EFNS task force. Eur. J. Neurol., 2009, 16<\/i>(9), 968\u2013981.","DOI":"10.1111\/j.1468-1331.2009.02748.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Larochelle, P., Tobe, S. W., Lacourci\u00e8re, Y.:<\/i> \u03b2-blockers in hypertension: studies and meta-analyses over the years. Can. J. Cardiol., 2014, 30<\/i>(5 Suppl.), S16\u2013S22.","DOI":"10.1016\/j.cjca.2014.02.012"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Holroyd, K. A., Penzien, D. B., Cordingley, G. E.:<\/i> Propranolol in the management of recurrent migraine: a meta-analytic review. Headache, 1991, 31<\/i>(5), 333\u2013 340.","DOI":"10.1111\/j.1526-4610.1991.hed3105333.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Linde, K., Rossnagel, K.:<\/i> Propranolol for migraine prophylaxis. Cochrane Database Syst. Rev., 2004, (2), CD003225.","DOI":"10.1002\/14651858.CD003225.pub2"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Bangalore, S., Sawhney, S., Messerli, F. H.:<\/i> Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J. Am. Coll. Cardiol., 2008, 52<\/i>(18), 1482\u20131489.","DOI":"10.1016\/j.jacc.2008.06.048"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Wiysonge, C. S., Bradley, H. A., Volmink, J., et al.:<\/i> Beta-blockers for hypertension. Cochrane Database Syst. Rev., 2012, 8,<\/i> CD002003.","DOI":"10.1002\/14651858.CD002003.pub4"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Mancia, G., Fagard, R., Narkiewicz, K., et al.:<\/i> 2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J., 2013, 34<\/i>(28), 2159\u2013 2219.","DOI":"10.1093\/eurheartj\/eht151"},{"key":"17","unstructured":"Neal, M. J.:<\/i> Medical Pharmacology at a Glance. 3rd edition. Blackwell Science Limited, Oxford, 2000."},{"key":"18","doi-asserted-by":"crossref","unstructured":"Rizos, C. V., Elisaf, M. S.:<\/i> Antihypertensive drugs and glucose metabolism. World J. Cardiol., 2014, 6<\/i>(7), 517\u2013 530.","DOI":"10.4330\/wjc.v6.i7.517"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Pringsheim, T., Davenport, W. J., Becker, W. J.:<\/i> Prophylaxis of migraine headache. CMAJ, 2010, 182<\/i>(7), E269\u2013E276.","DOI":"10.1503\/cmaj.081657"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Reveiz-Herault, L., Cardona, A. F., Ospina, E. G., et al.:<\/i> Effectiveness of flunarizine in the prophylaxis of migraine: a meta-analytical review of the literature. Rev. Neurol., 2003, 36<\/i>(10), 907\u2013912.","DOI":"10.33588\/rn.3610.2002450"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Bisol, L. W., Brunstein, M. G., Ottoni, G. L., et al.:<\/i> Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia. J. Clin. Psychiatry, 2008, 69<\/i>(10), 1572\u2013 1579.","DOI":"10.4088\/JCP.v69n1007"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Bondon-Guitton, E., Perez-Lloret, S., Bagheri, H., et al.:<\/i> Drug-induced parkinsonism: a review of 17 years\u2019 experience in a regional pharmacovigilance center in France. Mov. Disord., 2011, 26<\/i>(12), 2226\u2013 2231.","DOI":"10.1002\/mds.23828"},{"key":"23","unstructured":"Modi, S., Lowder, D. M.:<\/i> Medications for migraine prophylaxis. Am. Fam. Physician, 2006, 73<\/i>(1), 72\u201378."},{"key":"24","doi-asserted-by":"crossref","unstructured":"Vaughan Williams, E. M.:<\/i> Classifying antiarrhythmic actions: by facts or speculation. J. Clin. Pharmacol., 1992, 32<\/i>(11), 964\u2013 977.","DOI":"10.1002\/j.1552-4604.1992.tb03797.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Leonard, L., Phillips, W. J.:<\/i> Near-complete migraine prophylaxis with amlodipine: a case report. J. Pain Symptom Manage., 2007, 34<\/i>(6), 571\u2013 573.","DOI":"10.1016\/j.jpainsymman.2007.08.004"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Ghamami, N., Chiang, S. H., Dormuth, C., et al.:<\/i> Time course for blood pressure lowering of dihydropyridine calcium channel blockers. Cochrane Database Syst. Rev., 2014, 8,<\/i> CD010052.","DOI":"10.1002\/14651858.CD010052.pub2"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Shamliyan, T. A., Choi, J. Y., Ramakrishnan, R., et al.:<\/i> Preventive pharmacologic treatments for episodic migraine in adults. J. Gen. Intern. Med., 2013, 28<\/i>(9), 1225\u2013 1237.","DOI":"10.1007\/s11606-013-2433-1"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Schrader, H., Stovner, L. J., Helde, G., et al.:<\/i> Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ, 2001, 322<\/i>(7277), 19\u2013 22.","DOI":"10.1136\/bmj.322.7277.19"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Schuh-Hofer, S., Flach, U., Meisel, A., et al.:<\/i> Efficacy of lisinopril in migraine prophylaxis \u2013 an open label study. Eur. J. Neurol., 2007, 14<\/i>(6), 701\u2013703.","DOI":"10.1111\/j.1468-1331.2007.01764.x"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Stovner, L. J., Linde, M., Gravdahl, G. B., et al.:<\/i> A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia, 2013, 34<\/i>(7), 523\u2013532.","DOI":"10.1177\/0333102413515348"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Yusuf, S., Teo, K. K., Pogue, J., et al.:<\/i> Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med., 2008, 358<\/i>(15), 1547\u20131559.","DOI":"10.1056\/NEJMoa0801317"},{"key":"32","doi-asserted-by":"crossref","unstructured":"D\u2019Amico, D.:<\/i> Pharmacological prophylaxis of chronic migraine: a review of double-blind placebo-controlled trials. Neurol. Sci., 2010, 31<\/i>(Suppl. 1), S23\u2013S28.","DOI":"10.1007\/s10072-010-0268-7"}],"container-title":["Orvosi Hetilap"],"original-title":[],"language":"hu","link":[{"URL":"https:\/\/www.akademiai.com\/doi\/pdf\/10.1556\/OH.2015.30056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T16:04:30Z","timestamp":1651075470000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/doi\/10.1556\/oh.2015.30056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1556\/OH.2015.30056"],"URL":"https:\/\/doi.org\/10.1556\/oh.2015.30056","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}